Neurocrine Biosciences (NBIX) Interest Expenses (2011 - 2026)

Neurocrine Biosciences' Interest Expenses history runs 15 years deep, the most recent figure standing at $590.2 million for Q1 2026.

• Quarterly Interest Expenses rose 6246.24% year-over-year to $590.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $590.2 million (up 2135.61% YoY) and the FY2025 annual result came in at $97.3 million, down 13.28% from the prior year.
• Interest Expenses was $590.2 million for Q1 2026 at Neurocrine Biosciences, up from $37.8 million in the prior quarter.
• Across five years, Interest Expenses topped out at $636.5 million in Q2 2025 and bottomed at -$5.6 million in Q4 2022.
• A 5-year average of $139.6 million and a median of $9.3 million in 2025 frame the typical range for Interest Expenses.
• Annual changes were most pronounced in 2022 — Interest Expenses slumped 126.05% — and 2026, when it soared 6246.24%.
• Neurocrine Biosciences' Interest Expenses stood at -$5.6 million in 2022, then soared by 133.93% to $1.9 million in 2023, then jumped by 378.95% to $9.1 million in 2024, then surged by 315.38% to $37.8 million in 2025, then jumped by 1461.38% to $590.2 million in 2026.
• Business Quant data shows NBIX's Interest Expenses at $590.2 million in Q1 2026, $37.8 million in Q4 2025, and $619.5 million in Q3 2025.